scholarly article | Q13442814 |
P50 | author | Róbert Wagner | Q57119081 |
Hans-Ulrich Häring | Q63256451 | ||
Andreas Fritsche | Q87609923 | ||
Elko Randrianarisoa | Q87788993 | ||
Nils Heyne | Q91662869 | ||
Martina Guthoff | Q91662875 | ||
Erifili Hatziagelaki | Q117216328 | ||
P2093 | author name string | Andreas Peter | |
P2860 | cites work | A new equation to estimate glomerular filtration rate | Q24651973 |
suPAR: the molecular crystal ball | Q28263862 | ||
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus | Q30426632 | ||
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis | Q33872298 | ||
Diabetic nephropathy: diagnosis, prevention, and treatment | Q34379284 | ||
Blocking αVβ3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats. | Q34441673 | ||
Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease | Q34787780 | ||
Microvascular complications of impaired glucose tolerance. | Q35591509 | ||
Soluble Urokinase Receptor and Chronic Kidney Disease. | Q36429637 | ||
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation | Q36987307 | ||
A new paradigm to understand and treat diabetic neuropathy. | Q38195562 | ||
Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes | Q42924246 | ||
Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes | Q43511438 | ||
Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study | Q44372241 | ||
Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria). | Q44717786 | ||
The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. | Q51365869 | ||
Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. | Q51723464 | ||
Modification of kidney barrier function by the urokinase receptor. | Q53510545 | ||
The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body w | Q59299925 | ||
Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo | Q72344903 | ||
Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group | Q73250901 | ||
Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study | Q74181586 | ||
Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? | Q81402639 | ||
The estimation of average hazard ratios by weighted Cox regression | Q83921596 | ||
Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy | Q85570577 | ||
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis | Q87055318 | ||
A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease | Q87105637 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | type 2 diabetes | Q3025883 |
P304 | page(s) | 40627 | |
P577 | publication date | 2017-01-16 | |
P1433 | published in | Scientific Reports | Q2261792 |
P1476 | title | Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus | |
P478 | volume | 7 |
Q42265982 | Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation |
Q47854753 | Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children |
Q38718670 | Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors |
Q90372112 | Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease |
Q57243215 | Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood |
Q38754939 | Extrarenal determinants of kidney filter function |
Q64097684 | Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease |
Q57189799 | Mechanisms underlying modulation of podocyte TRPC6 channels by suPAR: Role of NADPH oxidases and Src family tyrosine kinases |
Q96577243 | Senolytic CAR T cells reverse senescence-associated pathologies |
Q33741426 | Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus. |
Q38685434 | Unwinding focal segmental glomerulosclerosis |
Q39423366 | suPAR and chronic kidney disease-a podocyte story. |